title: Long-term immunogenicity of hepatitis A virus vaccine in Alaska 17 years after initial childhood series.
abstract: The Centers for Disease Control and Prevention recommends hepatitis A virus (HAV) vaccination for all children at age 1 year and for high-risk adults. The vaccine is highly effective; however, protection duration is unknown. We report HAV antibody concentrations 17 years after childhood immunization, demonstrating that protective antibody levels remain and have stabilized over the past 7 years.
authors.affiliation: Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. graczniak@cdc.gov
authors.forename: Gregory A
authors.initials: GA
authors.lastname: Raczniak
authors.forename: Lisa R
authors.initials: LR
authors.lastname: Bulkow
authors.forename: Michael G
authors.initials: MG
authors.lastname: Bruce
authors.forename: Carolyn L
authors.initials: CL
authors.lastname: Zanis
authors.forename: Richard L
authors.initials: RL
authors.lastname: Baum
authors.forename: Mary M
authors.initials: MM
authors.lastname: Snowball
authors.forename: Kathy K
authors.initials: KK
authors.lastname: Byrd
authors.forename: Umid M
authors.initials: UM
authors.lastname: Sharapov
authors.forename: Thomas W
authors.initials: TW
authors.lastname: Hennessy
authors.forename: Brian J
authors.initials: BJ
authors.lastname: McMahon
mesh_terms: D000293:Adolescent; D000328:Adult; D000413:Alaska; D002648:Child; D002675:Child, Preschool; D005500:Follow-Up Studies; D006506:Hepatitis A / Q000276:immunology* / Q000517:prevention & control*; D035922:Hepatitis A Antibodies / Q000097:blood / Q000276:immunology; D022362:Hepatitis A Vaccines / Q000276:immunology*; D030041:Hepatitis A virus / Q000276:immunology*; D006801:Humans; D055815:Young Adult
chemical_list: D035922:Hepatitis A Antibodies; D022362:Hepatitis A Vaccines